An observational study in Cardiogenic Shock, IABC Procedure and Intraaortic Balloon Counterpulsation (IABC), sponsored by Thomas Jefferson University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-11.
Sponsored by Thomas Jefferson University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies in Shock, Cardiogenic with a site in United States — 19 open to participants now, 23 under way, none of them phase 3. Shock, Cardiogenic · United States.
Among the 50 studies in Shock, Cardiogenic with a site in United States, this one is the 21st largest by planned enrollment of the 25 observational ones that give a count, is one of 5 that started in 2026, is one of 25 observational ones, reaches primary completion later than 1 of the 22 other live ones, and was the 46th registered.
297 studies on the registry are indexed under Shock, Cardiogenic; 134 are open to participants now.
Browse Shock, Cardiogenic studies →19 of the 50 studies in Shock, Cardiogenic with a site in United States are open now. Recruiting first, the newest first:
Abiomed Inc. · Sites in United States
Ages 18–80
Mayo Clinic · Sites in United States
Ages 18+
Atlantic Health System · Sites in United States
Ages 18–100
Abiomed Inc. · Sites in United States
Ages 18+
NIRSense Inc. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 101 Shock, Cardiogenic studies recruiting now, 70 (69%) set no upper age limit and 9 (9%) stop at 75 or younger; 11 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 3 1 · Phase 4 3
First in 2005; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 200 across 156 observational studies indexed under Shock, Cardiogenic.
Median enrollment 30 across the 25 interventional studies, 124 across the 25 observational. Of the 20 that completed or were terminated, 6 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 50 have an industry lead sponsor. The 10 most frequent:
Thomas Jefferson University is the lead sponsor of 394 studies on the registry; 69 are open to participants now.
Of its 45 completed or terminated interventional studies of FDA-regulated products, 21 (47%) have results posted.
Thomas Jefferson University has 1 study filed under Shock, Cardiogenic — fewer than ten, so there is no comparison to draw.
11 of the studies in Shock, Cardiogenic with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05267886Ottawa Heart Institute Research CorporationCAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock | 2026-12 |
| NCT05800951Henry Ford Health SystemCan Escalation Reduce Acute Myocardial Infarction Mortality in Cardiogenic Shock | 2026-12-31 |
| NCT06253104Tufts Medical CenterChanges in Skeletal Muscle Thickness in Patients With Acute Heart Failure | 2026-12-31 |
| NCT07402018Thomas Jefferson UniversityIntra-aortic Balloon Counterpulsation (IABC) Compliance | 2026-12-31 |
| NCT07825363NIRSense Inc.Clinical Evaluation of NIRSense Tissue Oximetry Sensor Monitoring to Early Detect Cardiogenic Shock | 2027-01 |
Add all 11 to your calendar (.ics) → With an account.
Among the 50 studies in Shock, Cardiogenic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The investigators intend to study how baseline arterial compliance (as defined by stroke volume/pulse pressure) influences the clinical success of intraaortic balloon counterpulsation (IABC) in patients with cardiogenic shock (CS). The investigators aim to compare clinical outcomes in CS patients requiring IABC with normal compliance versus low compliance. The study will enroll patients undergoing IABC that are clinically indicated. Baseline hemodynamic measurements will be obtained and then patients would be stratified based on their compliance. Post IABC, serial hemodynamic measurements will be obtained and compared between groups. Patients will continue to be followed longitudinally until the IABC has been discontinued for any reason. The proposed study will yield results that will aid in developing a larger clinical trial and ultimately assist clinicians in determining if IABC is appropriate therapy for patients in cardiogenic shock.
This study will focus on patients in cardiogenic shock (CS) that will be undergoing clinically indicated intraaortic balloon counterpulsation (IABC) insertion and right heart catheterization. Prior to IABC insertion a patient will have their clinically indicated right heart catheterization. The investigators will record these baseline hemodynamic parameters, including (but not limited to) stroke volume and arterial pulse pressure.
After IABC insertion is completed, repeat hemodynamic measurements will be obtained approximately 30 minutes later. Repeat hemodynamic measurements will be recorded at approximately 3-6 hours following the procedure, and 24 hours following the procedure. The act of recording hemodynamic measurements is part of the usual clinical management of patients with IABC.
The patients will continue be followed longitudinally until their IABC course has completed, either due to resolution of CS, exchange for a separate device, heart transplantation, durable Left Ventricular Assist Device (LVAD) implant, or patient death.
The investigators hypothesize that patients with low arterial compliance will have greater improvements in cardiac output and cardiac filling pressures compared to patients with normal compliance. The specific aims are to (1) compare hemodynamic changes with IABC in cardiogenic shock patients with low compliance vs those with normal compliance and (2) to determine a cutoff value of compliance that can be used for future larger clinical trials.
The proposed study will yield results that will aid in developing a larger clinical trial and ultimately assist clinicians in determining if IABC is appropriate therapy for patients in cardiogenic shock.
Cardiogenic shock patients undergoing Intra-aortic Balloon Counterpulsation
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Cardiac Output (L/min)
Time frame: 24 hours
Systolic Blood Pressure (mmHg)
Time frame: 30 minutes
Pulmonary Artery Oxygen Saturation (%)
Time frame: 24 hours
Ultimate Disposition
Hospital death
Time frame: Longitudinal Follow-Up (approximately 3 months)
Total Bilirubin (mg/dL)
participant laboratory value
Time frame: 24 hours
ALT (U/L)
participant laboratory value
Time frame: 24 hours
AST (U/L)
participant laboratory value
Time frame: 24 hours
Creatine Clearance/GFR
Time frame: 24 hours
Creatine (mg/dL)
participant laboratory value
Time frame: 24 hours
Lactate millimoles per liter (mmol/L)
participant laboratory value
Time frame: 24 hours
Pulmonary Artery Compliance (mmHg)
Time frame: 24 hours
Right Ventricular Stroke Work Index (g·m-²·beat-¹)
Time frame: 24 hours
Pulmonary Artery Pulsatility Index (PAPi)
calculated measurement
Time frame: 24 hours
Pulmonary Vascular Resistance (dynes/cm⁵)
Time frame: 24 hours
Systemic Vascular Resistance (mmHg/L/min)
Time frame: 24 hours
Pulmonary Capillary Wedge Pressure (mmHg)
Time frame: 24 hours
Diastolic Pulmonary Arterial Pressure (mmHg)
Time frame: 24 hours
Systolic Pulmonary Artery Pressure (mmHg)
Time frame: 24 hours
Right Atrium Pressure (mmHg)
report measurement
Time frame: 24 hours
Aortic Pulsatility Index (API)
calculated measurement
Time frame: 24 hours
Cardiac Power Input (W/m²)
Time frame: 24 hours
Cardiac Power Output (Watts)
Time frame: 24 hours
Stroke Volume (mL)
Time frame: 24 hours
Cardiac Index (L/min/m²)
Time frame: 24 hours
Heart Rhythm
Normal Sinus Rhythm, Atrial Fibrillation, Atrial Flutter, Ventricular Fibrillation, Ventricular Tachycardia, Sinus Bradycardia, Sinus Tachycardia, other
Time frame: 24 hours
Heart Rate (beats per minute)
Time frame: 24 hours
Mean Arterial Pressure (mmHg)
Time frame: 24 hours
Diastolic Blood Pressure (mmHg)
Time frame: 24 hours
Systolic Blood Pressure (mmHg)
Time frame: 24 hours
Pulmonary Artery Compliance (mmHg)
Time frame: 3-6 hours
Right Ventricular Stroke Work Index (g·m-²·beat-¹)
Time frame: 3-6 hours
Pulmonary Artery Pulsatility Index (PAPi)
calculated measurement
Time frame: 3-6 hours
Pulmonary Vascular Resistance (dynes/cm⁵)
Time frame: 3-6 hours
Systemic Vascular Resistance (mmHg/L/min)
Time frame: 3-6 hours
Pulmonary Capillary Wedge Pressure (mmHg)
Time frame: 3-6 hours
Diastolic Pulmonary Arterial Pressure (mmHg)
Time frame: 3-6 hours
Systolic Pulmonary Artery Pressure (mmHg)
Time frame: 3-6 hours
Right Atrium Pressure (mmHg)
report measurement
Time frame: 3-6 hours
Aortic Pulsatility Index (API)
calculated measurement
Time frame: 3-6 hours
Cardiac Power Input (W/m²)
Time frame: 3-6 hours
Cardiac Power Output (Watts)
Time frame: 3-6 hours
Stroke Volume (mL)
Time frame: 3-6 hours
Cardiac Index (L/min/m²)
Time frame: 3-6 hours
Cardiac Output (L/min)
Time frame: 3-6 hours
Pulmonary Artery Oxygen Saturation (%)
Time frame: 3-6 hours
Heart Rhythm
Normal Sinus Rhythm, Atrial Fibrillation, Atrial Flutter, Ventricular Fibrillation, Ventricular Tachycardia, Sinus Bradycardia, Sinus Tachycardia, other
Time frame: 3-6 hours
Heart Rate (beats per minute)
Time frame: 3-6 hours
Mean Arterial Pressure (mmHg)
Time frame: 3-6 hours
Diastolic Blood Pressure (mmHg)
Time frame: 3-6 hours
Systolic Blood Pressure (mmHg)
Time frame: 3-6 hours
Pulmonary Artery Compliance (mmHg)
Time frame: 30 minutes
Right Ventricular Stroke Work Index (g·m-²·beat-¹)
Time frame: 30 minutes
Pulmonary Artery Pulsatility Index (PAPi)
calculated measurement
Time frame: 30 minutes
Pulmonary Vascular Resistance (dynes/cm⁵)
Time frame: 30 minutes
Systemic Vascular Resistance (mmHg/L/min)
Time frame: 30 minutes
Pulmonary Capillary Wedge Pressure (mmHg)
Time frame: 30 minutes
Diastolic Pulmonary Arterial Pressure (mmHg)
Time frame: 30 minutes
Systolic Pulmonary Artery Pressure (mmHg)
Time frame: 30 minutes
Right Atrium Pressure (mmHg)
report measurement
Time frame: 30 minutes
Aortic Pulsatility Index (API)
calculated measurement
Time frame: 30 minutes
Cardiac Power Input (W/m²)
Time frame: 30 minutes
Stroke Volume (mL)
Time frame: 30 minutes
Cardiac Power Output (Watts)
Time frame: 30 minutes
Cardiac Index (L/min/m²)
Time frame: 30 minutes
Cardiac Output (L/min)
Time frame: 30 minutes
Pulmonary Artery Oxygen Saturation (%)
Time frame: 30 minutes
Heart Rhythm
Normal Sinus Rhythm, Atrial Fibrillation, Atrial Flutter, Ventricular Fibrillation, Ventricular Tachycardia, Sinus Bradycardia, Sinus Tachycardia, other
Time frame: 30 minutes
Heart Rate (beats per minute)
Time frame: 30 minutes
Mean Arterial Pressure (mmHg)
Time frame: 30 minutes
Diastolic Blood Pressure (mmHg)
Time frame: 30 minutes
Ultimate Disposition
Heart recovery with discharge (alive)
Time frame: Longitudinal Follow-Up (approximately 3 months)
Ultimate Disposition
Left Ventricular Assist Device (LVAD)
Time frame: Longitudinal Follow-Up (approximately 3 months)
Ultimate Disposition
Transplant
Time frame: Longitudinal Follow-Up (approximately 3 months)
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Dec 2026, 11 months after the start.
Of 79 non-industry observational studies under Shock, Cardiogenic, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 19. This study's planned 11 months is below that.
Counting every sponsor, half of 85 studies reached it within 45 months; a quarter within 24.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.